Supercharging a New FDA: Marty Makary on Science, Power & Patients

概览

FDA Commissioner Marty Makary sits down with Dave at the JPMorgan Healthcare Conference to discuss his first year in the role, the administration’s FDA reform agenda, and his view that U.S. health institutions must rebuild public trust after COVID-era decisions.

The core theme is speed with accountability: Makary argues that drug development timelines, internal FDA workflows, animal testing rules, clinical trial structures, drug pricing, and public-health guidance all need modernization. He frames many reforms as a response to bureaucracy, medical dogma, and global competition from China and Australia.

The conversation then broadens from biotech regulation into food policy, chronic disease, vaccines, pharma advertising, AI medical tools, alternative proteins, autism, the microbiome, and frontier therapies. Across these topics, Makary repeatedly emphasizes transparency, “common sense,” root-cause research, and a less paternalistic medical system.

分段落总结

[00:00] Opening and Makary’s Path to the FDA

[事实] The episode begins at the JPMorgan Healthcare Conference in San Francisco, which Dave describes as one of the most important global biotech conferences. [事实] Makary says his background includes public health, Johns Hopkins faculty work, GI and cancer surgery, and research interests in healthcare quality, transparency, and price. [事实] He says his work on hospital price transparency helped connect him with the first Trump administration, which later implemented an executive order on the issue. [事实] He says President Trump called him days after reelection and offered him the FDA Commissioner role.

[02:00] COVID, Medical Dogma, and Public Trust

[事实] Makary criticizes COVID-era policies including cloth masks on toddlers, vaccine mandates for young college students, boosters for healthy children, ignoring natural immunity, and prolonged school closures. [事实] He says he and others, including Jay Bhattacharya, argued for reopening schools once data emerged in 2020. [推测] His COVID critique sets up the broader philosophy of the episode: medical authorities should be willing to revisit assumptions when evidence changes.

[04:00] Changing FDA Culture and Transparency

[事实] Makary says private conversations with individual FDA reviewers produced reform ideas that would not surface in larger meetings with supervisors present. [事实] He says the FDA announced 42 major reforms in his first 10 months. [事实] He cites public rejection letters, new priority reviews, pilots, and transparency measures as examples. [事实] He says the agency moved to remove nine artificial petroleum-based food dyes within weeks of his arrival.

[06:00] Staffing, Morale, and Mission Reset

[事实] Makary says the FDA had about 20,000 employees before he arrived, including 2,000 HR staff and 1,500 IT staff. [事实] He says restructuring reduced HR, procurement, IT, and duplicative services, but did not lay off scientific reviewers. [事实] He rejects claims of mass departures, saying turnover remains at a 5% to 7% baseline. [事实] He says the FDA is hiring 1,050 new scientists to support accelerated pathways.

[08:00] U.S.-China Biotech Competition

[事实] Dave cites a biotechnology commission report saying the U.S. has a three-year window to keep pace with China’s biotech innovation. [事实] Makary says there is a race and that the U.S. was losing when the administration entered office. [事实] He argues the U.S. needs to compete on speed and efficiency, not only protectionist policy. [事实] He identifies slow IRBs, hospital contracting, INDs, and phase-one processes as major bottlenecks.

[12:00] FDA Timelines and Clinical Trial Reform

[事实] Makary says he wants higher user fees for phase-one trials done overseas and lower fees for trials done in the United States. [事实] He says the FDA hit 100% of its user-fee target dates in 2025. [事实] He explains the drug-development sequence as IND, phase one in healthy subjects, phase two in patients with the condition, and phase three as a large pivotal trial. [事实] He says the FDA moved from a default of two pivotal trials to one well-designed pivotal trial.

[14:00] Animal Testing, Modeling, and Organ-on-Chip

[事实] Makary says the FDA is reducing animal testing requirements, including no longer requiring chimpanzee studies for monoclonal antibodies. [事实] He argues animal studies can be misleading and says 90% of drugs that pass animal studies do not pass human safety and efficacy. [事实] He points to computational modeling and organ-on-chip technology as modern alternatives. [推测] He presents animal-testing reform as both an ethical issue and a competitiveness issue.

[16:00] Priority Vouchers and Faster Decisions

[事实] Makary says FDA drug approvals taking 10 to 12 years makes no sense in the modern scientific environment. [事实] He says a new pilot program aims to produce decisions in weeks, with one medication announced after 55 days. [事实] He says vouchers are given for products aligned with national priorities: unmet public-health needs, bringing manufacturing back to the U.S., or making drugs affordable. [事实] He says about 18 products have vouchers under the pilot program.

[20:00] Continuous Trials and Bayesian Statistics

[事实] Makary says the FDA announced it will allow Bayesian statistics. [事实] He supports continuous trials with endpoints in the cloud, so reviewers can monitor safety and efficacy signals in real time. [事实] He criticizes the current model of submitting huge applications after each development stage. [推测] The proposed approach would shift FDA review from episodic paperwork toward ongoing data evaluation.

[22:00] Post-Market Surveillance and Safety Signals

[事实] Makary says approval should not be the end of monitoring and that the FDA should keep “eyes on a drug” after approval. [事实] He cites Vioxx and opioids as examples where safety signals or national patterns were recognized too late. [事实] He says big-data post-market surveillance could identify subgroup risks or drug-drug interactions sooner. [推测] He implies that stronger post-market monitoring could justify faster initial approvals.

[24:00] Risk, Delay, and Right to Try

[事实] Dave asks how to explain that delays themselves can cost lives when patients are waiting for therapies. [事实] Makary says safety is the FDA’s number-one priority, but unnecessary delays also create risks for patients. [事实] He says he believes in both the letter and spirit of Right to Try and has signed 100% of requests that reached his desk. [事实] He says companies still have to agree to make the medication available.

[26:00] Cell and Gene Therapy Flexibility

[事实] Makary says the FDA is removing some regulatory requirements for cell and gene therapy. [事实] He says manufacturing requirements should be customized to the drug and patient population rather than applied as one hard rule. [事实] He describes a “plausible mechanism pathway” for bespoke therapies where randomized trials may not be practical. [事实] He says CAR-T therapies are promising and could benefit from faster, lower-cost routes to market.

[30:00] FDA Silos, Digitization, and Restructuring

[事实] Makary says the FDA had siloed centers that sometimes could not easily share information, including an example of a drug file being carried physically between buildings. [事实] He says the FDA had seven centers with separate boundaries, communications, legislative affairs, and other functions. [事实] He says the agency centralized services and restructured to reduce fragmentation. [事实] He describes the old structure as difficult for developers of drug-device combination products.

[32:00] Food Pyramid and Nutrition Dogma

[事实] Makary says past food pyramids were scientifically inaccurate and influenced by food-industry-linked nutrition science. [事实] He criticizes decades of focus on saturated fat while refined carbohydrates and added sugar increased in the food supply. [事实] He says 38% of kids have prediabetes or diabetes and that 60% to 70% of children’s calories come from refined carbohydrates. [事实] He says the new guidance flips the food pyramid and emphasizes protein.

[40:00] Real Food, Insulin Resistance, and Protein

[事实] Makary says insulin resistance and general body inflammation are root factors in many chronic diseases. [事实] He rejects “calories in equals calories out” as an adequate nutrition framework. [事实] He says the new guidance discusses food sources, farming techniques, seafood quality, protein, whole grains, and “real food.” [事实] Dave says he would like more vegetarian protein, such as nuts and beans, represented near the top of the pyramid.

[42:00] GLP-1 Drugs and the Food System

[事实] Dave asks whether widespread use of GLP-1 drugs would mean the food system has failed. [事实] Makary says the food system has failed, citing chronic disease among children and addictive ultra-processed foods. [事实] He says GLP-1s mimic a natural hormone, increase satiety, slow GI motility, and may reduce insulin resistance and inflammation. [推测] Makary views GLP-1 drugs as therapeutically useful but not a substitute for fixing food and lifestyle drivers.

[44:00] NIH Funding and Root-Cause Research

[事实] Dave asks about claims that the Trump administration is anti-science and is defunding research institutions. [事实] Makary says the administration has not cut NIH funding or the overall Medicaid fund. [事实] He says the goal is to reallocate NIH money toward food as medicine, school lunches, microbiome research, gut health, sleep, and environmental causes of disease. [事实] He says too much prior focus went to genetics and treatment rather than disease causes.

[48:00] DEI Research and NIH Reform

[事实] Makary says 14% of NIH grants went to DEI research. [事实] He says he supports reducing health disparities and improving access, but argues that many grants merely described disparities rather than solving them. [事实] He says the FDA has emphasized hormone replacement therapy for post-menopausal women after decades of demonization. [事实] He praises Jay Bhattacharya’s NIH reform work.

[50:00] Vaccines, Hepatitis B, and Public Trust

[事实] Dave says his family declined the hepatitis B vaccine on the day his child was born because they saw no household exposure risk. [事实] Makary says his family also declined the hepatitis B shot for their newborn. [事实] He says hepatitis B is sexually transmitted or blood-borne and questions giving it in the first hour of life when the mother is hepatitis B negative. [事实] He says the U.S. vaccine schedule was an international outlier with 72 recommended doses from ages 0 to 18.

[52:00] Core Essential Vaccines

[事实] Makary says the administration reviewed vaccine recommendations across 20 developed countries. [事实] He says the CDC still recommends all vaccines, but the administration presented a hierarchy of core essential vaccines totaling about 38 doses. [事实] He says the goal is to increase vaccination rates by rebuilding trust among parents who became skeptical after COVID-era absolutism. [推测] The strategy is to distinguish higher-priority vaccines from lower-priority ones rather than treating every recommendation as identical.

[56:00] Vaccine Politics and Scientific Humility

[事实] Dave asks how to reduce political conflict around vaccine schedules, including states setting their own schedules. [事实] Makary says toxic polarization has entered medicine and that credentials have not prevented character attacks. [事实] He names anthrax, H3N3, and a 1999 rotavirus vaccine as examples of vaccines that had serious problems or were removed from the market. [事实] He says medicine should respond to parent questions with humility rather than absolutism.

[58:00] Drug Pricing and Most-Favored-Nation Policy

[事实] Makary calls high U.S. drug prices “the great American ripoff.” [事实] He says a GLP-1 drug costing $1,300 in the U.S. can sell for $88 in London. [事实] He says President Trump wants the U.S. to receive the best price in the developed world through most-favored-nation pricing. [事实] He says drug companies came to the table and agreed to pricing changes, including lowering a GLP-1 example to $149 for the first three months.

[61:00] Biosimilars and Over-the-Counter Access

[事实] Makary says biologics are the fastest-growing area of drug spending and that biosimilars have been slowed by FDA red tape. [事实] He says the FDA changed biosimilar requirements to reduce R&D costs by more than $100 million and shorten timelines from five to eight years to about two and a half years or more. [事实] He argues many drugs should move from prescription to over-the-counter status if they are safe, lack abuse potential, do not require lab monitoring, and cannot be misused to make dangerous street drugs. [事实] He says over-the-counter shelf pricing would improve price transparency and bypass some PBM dynamics.

[68:00] Pharma Advertising and Enforcement

[事实] Dave raises the debate over direct-to-consumer pharmaceutical advertising and media influence. [事实] Makary says patient awareness can be good, but misleading ads can create inappropriate demand. [事实] He says the FDA must enforce rules requiring ads not to mislead and to provide fair balance of information. [事实] He says he sent 1,500 enforcement letters, including more than 100 cease-and-desist letters, after the prior year had zero such letters.

[71:00] AI Medical Tools and Wearables

[事实] Makary says AI generates information faster than traditional regulatory systems can keep up. [事实] He says the FDA should distinguish consumer information tools from automated AI that triggers health interventions. [事实] He says new guidance creates a consumer lane for AI decision support and wearables. [事实] He says devices can report physiological parameters, but “medical grade” claims require validation against gold-standard measurements.

[74:00] Alternative Proteins and GRAS Reform

[事实] Dave asks about precision-fermented proteins, cellular meat, and the GRAS system. [事实] Makary explains GRAS as a process that allowed companies to self-declare food additives as safe. [事实] He says GRAS began with reasonable items like salt but was later abused by engineered chemicals getting a free pass. [事实] He says the FDA started the regulatory process to close the GRAS loophole.

[78:00] Cellular Foods, Autism, and Early Hypotheses

[事实] Makary says new cellular food products, including seafood, have appeared during his FDA tenure. [事实] He says the FDA does not have jurisdiction over what someone creates at the state level but asks for registration to stay in the loop. [事实] Asked what causes autism, he says he does not know, but says diagnoses have increased and cites one in 12 boys in California being diagnosed. [事实] He describes a hypothesis involving antibodies blocking folate receptors and leucovorin bypassing that blocked receptor.

[80:00] Microbiome and Neurodevelopment

[事实] Makary says the microbiome produces molecules involved in brain health and says 90% of the body’s serotonin is made in the gut. [事实] He lists C-sections, infant formula instead of breast milk, and heavy antibiotic use as factors that can harm the microbiome. [事实] He says the average two-year-old has received more than 2.5 courses of antibiotics. [事实] He says a randomized trial found improvement in children with autism after a certain protease, but adds that it needs replication and that he does not know if it is real.

[84:00] Inflammation, Saturated Fat, and Chronic Disease

[事实] Makary says chemicals and denatured proteins in the GI tract may produce low-grade inflammation. [事实] He says many chronic diseases relate to general body inflammation and insulin resistance. [事实] He says three large studies failed to show a clear association between normal saturated fat intake and heart disease. [事实] He cites the Minnesota Heart Study as showing results opposite to expectations and says the results were suppressed for 16 years.

[85:00] Frontiers in Human Health

[事实] Makary says the FDA tries to act as a referee among competing technologies rather than pick winners early. [事实] He says he wants to see meaningful treatments or cures for type 1 diabetes, ALS, certain cancers, universal flu protection, and PTSD. [事实] He highlights PD-1 blockers and KRAS inhibitors as cancer treatments that can make tumors shrink enough to avoid surgery or chemotherapy. [事实] He says more than 7,000 veterans a year are still lost to suicide and calls PTSD treatment a personal goal if the data supports it.

[88:00] Pipeline Examples and FDA Speed

[事实] Makary says he asks FDA reviewers privately whether they see anything early in the pipeline that could be a game changer. [事实] He cites a gene therapy-device treatment for a type of congenital deafness, saying about a dozen children received it and a couple had normal hearing. [事实] He cites a multiple myeloma treatment that he says was three times better than anything available and had about 80% remission-free survival at a couple of years. [事实] He says the FDA contacted that company and issued a voucher within 24 hours of an abstract appearing in pre-conference materials.

播客点评/总结

[推测] The episode’s strongest value is its unusually detailed view into how Makary wants the FDA to operate: faster reviews, fewer silos, more transparency, more real-world surveillance, and greater tolerance for new trial designs.

[推测] Its main limitation is that many claims are presented from Makary’s perspective without adversarial challenge or independent verification inside the transcript. Listeners interested in policy accuracy would need to compare these assertions against primary FDA, CDC, NIH, CMS, and clinical evidence sources.

[推测] The episode is most useful for biotech founders, healthcare investors, policy watchers, clinicians, and listeners interested in how regulation, drug pricing, nutrition policy, AI health tools, and public trust intersect under the current administration.